Date: 2012-10-22
Type of information: Fundraising
Company: Pharma Two B (Israel)
Investors:
Amount: $8 million
Funding type: financing round
Planned used: Financing will be used to continue the development of the company\'s Fixed-Dose-Combination product P2B001 for the treatment of Parkinson’s disease, and complete the pivotal Phase IIb clinical trial as part of the US FDA 505(b)(2) regulatory pathway the company chose to take.
Others: * On October 22, 2012, Pharma Two B, a privately held company focused on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, announced that it has completed its second round of financing and has raised $8 million. Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. The company focuses on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505(b)(2) approach). The company develops products in two therapeutic areas with great unmet needs, Parkinson\'s disease and Cancer.
Therapeutic area: Neurodegenerative diseases
